Cosentyx works for nail and palmoplantar psoriasis

[Fred]

Novartis have announced that Cosentyx is the first Bio to demonstrated long term efficacy and safety in nail and palmoplantar psoriasis.

Quote:

---

Novartis today announced first-of-its-kind long-term data showing that Cosentyx® (secukinumab) provided sustained improvements in nail and palmoplantar psoriasis out to 2.5 years. These data are unique as it is the first time any biologic has demonstrated long-term efficacy and safety in nail and palmoplantar psoriasis.

Up to 90% of psoriasis patients may develop nail psoriasis or palmoplantar psoriasis, which affects the palms of the hands and soles of the feet. Both nail and palmoplantar psoriasis heavily impact patients' quality of life leading to reduced mobility, functional impairment and physical discomfort.
Cosentyx addresses the cornerstone cytokine interleukin-17A (IL-17A) involved in the development and progression of psoriasis, and is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in psoriasis. By working to specifically target and inhibit IL-17A, Cosentyx can more effectively address the underlying cause of the disease. To date, psoriasis treatments targeting other, less direct, pathways have not shown long-term efficacy out to 2.5 years in these hard-to-treat forms.

"Patients with nail and palmoplantar psoriasis need effective treatment options to address the significant impact these conditions can have on their day-to-day lives," said Eric Hughes, Global Development Unit Head, Immunology & Dermatology. "As an IL-17A inhibitor, Cosentyx provides a highly targeted treatment option that can not only effectively treat the plaques caused by psoriasis, as evident by recently presented 5-year data, but also hard-to-treat forms and associated arthritic conditions."

In GESTURE, 59% and 53% palmoplantar psoriasis patients who received Cosentyx 300 mg and 150 mg respectively achieved clear or almost clear palms and soles at 2.5 years (as measured by Palmoplantar Investigator's Global Assessment (ppIGA) 0/1). In the TRANSFIGURE study, patients with nail psoriasis who were treated with Cosentyx 300 mg and 150 mg showed a substantial NAPSI (Nail Psoriasis Severity Index) improvement from baseline of -73% and -63% respectively. GESTURE, the largest and longest randomized controlled trial to date in palmoplantar psoriasis patients, and TRANSFIGURE, the first large, controlled trial to report long-term results in nail psoriasis, both demonstrated strong sustainability out to 2.5 years, with a favorable and consistent safety profile, including close to zero injection site reactions or associated pain.

Source: novartis.com

[Caroline]

Quote:

---

Cosentyx addresses the cornerstone cytokine interleukin-17A (IL-17A) involved in the development and progression of psoriasis, and is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in psoriasis. By working to specifically target and inhibit IL-17A, Cosentyx can more effectively address the underlying cause of the disease. To date, psoriasis treatments targeting other, less direct, pathways have not shown long-term efficacy out to 2.5 years in these hard-to-treat forms.

This is great news.... if I read it well, IL-17A, is the cause of the disease !!!!!
Or am I reading not correctly????

You know, I have always thought the cause is somewhere either located in the genes or in something like stubborn bacteria in your body, where the real problem, Psoriasis is triggered by causes like stress or trauma or otherwise.

IL-17A the cause?  I doubt it.
And I think I am reading it wrongly. It says:"Cosentyx can more effectively address the underlying cause of the disease."
It addresses the underlying cause. But what "is" the underlying cause? Apparantly Novartis knows it.
What I think is that IL-17A is blocked, at least that is the purpose of an inhibitor, so the effect is that the expression of the Psoriasis and specifically the arthritis, the inflammations, are prevented. But as far as I know the cause of the Psoriasis is not touched. It is only the expression.